Iadademstat

Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research[1].

Product Specifications

CAS Number

[1431304-21-0]

Product Name Alternative

ORY-1001

UNSPSC

12352005

Target

Apoptosis; Histone Demethylase

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/iadademstat.html

Concentration

10mM

Purity

99.82

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N[C@@H]1CC[C@@](CC1)([H])N[C@H]2[C@H](C3=CC=CC=C3)C2

Molecular Formula

C15H22N2

Molecular Weight

230.35

References & Citations

[1]Olga Salamero, et al. First-in-Human Phase I Study of Iadademstat (ORY-1001) : A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2020 Dec 20;38 (36) :4260-4273. |[2]Lu Z, et al., ORY-1001 Suppresses Cell Growth and Induces Apoptosis in Lung Cancer Through Triggering HK2 Mediated Warburg Effect. Front Pharmacol. 2018 Dec 4;9:1411.|[3]Yang H, et al., [ORY-1001 inhibits glioblastoma cell growth by downregulating the Notch/HES1 pathway via suppressing lysine-specific demethylase 1 expression]. Nan Fang Yi Ke Da Xue Xue Bao. 2024 Aug 20;44 (8) :1620-1630. Chinese.